ArticleResearch and practice in thrombosis and haemostasis2026
Adaption of the plasmin generation assay to enhance sensitivity to plasminogen activator inhibitor-1 and establishment of sex-specific reference values in human plasma.
Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pharmacologic modifiers of fibrinolysis are used to modulate bleeding and thrombosis. Characterization of a sensitive plasmin generation (PG) assay to identify abnormal fibrinolytic states and monitor antifibrinolytic medication may improve clinical care. Objectives: To establish reference values of PG parameters, investigate sex-related differences, and study different regulators of fibrinolysis, using a PG assay. Methods: PG was assessed in plasma of 130 healthy individuals, normal pooled plasma, or factor-deficient plasma, using tissue factor or Russell viper venom-factor (F)X activator, with tissue plasminogen activator or the novel antifibrin urokinase plasminogen activator. Results: Reference values for PG parameters were established in plasma from healthy individuals. No PG was observed in plasminogen- or fibrinogen-deficient plasma. Thrombomodulin (TM), α Conclusion: The PG assay is a specific and efficient tool to assess modulators of fibrinolysis and to study sex-related differences and has potential as a clinical tool to identify abnormal fibrinolytic profiles in patients and monitor antifibrinolytic drugs, such as tranexamic acid.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.